Clinical trials
Stem Cell Transplantation clinical trials
Below are recruiting stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 604 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07413978RecruitingPhase 1/Phase 2
Stem cell injection for severe ARDS
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
Wuhan, HubeiAges 18–80 - NCT04414046RecruitingPhase 2
Stem cell transplant using T-cell cleanup for immune and metabolism disorders
This Phase 2 study tests a specialized stem cell transplant that removes certain “T-cells” (a type of immune cell) to treat children with serious immune system or inherited metabolic problems. The goal is to improve or stabilize disease by resetting the immune system and supporting the body’s function.
St. Petersburg, FloridaAges Up to 21 years - NCT05509933RecruitingPhase 3
Budesonide to prevent engraftment syndrome after stem cell transplant
This Phase 3 study tests whether budesonide can prevent “engraftment syndrome” after people receive a hematopoietic (blood-forming) stem cell transplant. If it works, it may reduce complications around the time the new cells start growing and making blood cells.
Detroit, MichiganAges 18–80 - NCT05018858RecruitingPhase 1
Test stem cell infusion safety for lupus
This early-phase study tests whether an intravenous (through a vein) stem cell treatment made from donated umbilical cord tissue is safe for people with lupus. It focuses mainly on side effects and how well participants tolerate the infusion.
St John'sAges Any age - NCT05224960RecruitingPhase 2
Stem cell treatment for worsening liver cirrhosis
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
Lanzhou, GansuAges 18–75 - NCT04099082Recruiting
Predicting lung scarring after a specific viral infection
This study looks at how your immune response to a particular virus (PIV) might predict future lung scarring called bronchiolitis obliterans. It may help doctors better identify who is at higher risk after a stem cell transplant.
Paris, Île-de-France RegionAges 18 years+ - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35 - NCT05851105RecruitingEarly Phase 1
Study drug for severe alpha thalassemia in people needing regular transfusions
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
Nanning, GuangxiAges 12–35 - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Stanford, CaliforniaAges 18–80 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT05018767RecruitingPhase 1
Testing an IV stem cell treatment for aging frailty safety
This early study (Phase 1) tests whether a lab-made stem cell product given through an IV is safe in people with “aging frailty.” It looks mainly at side effects and safety while also exploring whether the treatment can be given safely.
St John'sAges Any age - NCT05773729Recruiting
Gene-modified own stem cell treatment for transfusion-dependent thalassemia
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
ShanghaiAges 3–18 - NCT07047456RecruitingPhase 3
Stem cell infusion timing and graft-versus-host disease risk in blood cancer patients
This trial looks at whether the time when stem cells are infused affects the chance of developing graft-versus-host disease (aGVHD) after a cord blood transplant. It may help find the best timing to improve outcomes for people with blood cancers.
Hefei, AnhuiAges Any age - NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
ShanghaiAges 6–35 - NCT07265349RecruitingPhase 1/Phase 2
Stem cells plus bypass surgery for chronic heart failure
This trial tests whether injecting stem cells from umbilical cord tissue into the heart muscle during bypass surgery can improve heart function in people with chronic heart failure. It is for patients who are already scheduled for bypass surgery and have a weakened heart pump (LVEF between 21% and 40%).
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07680803RecruitingPhase 2
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
Rome, LazioAges 3–35 - NCT06610773RecruitingPhase 1/Phase 2
Stem cell treatment for high-risk HPV infection
This trial tests whether umbilical cord stem cells can help clear a persistent high-risk HPV infection. It is for women aged 25 to 60 who have had HPV for a while and have not been treated with other HPV drugs recently.
Shanghai, Shanghai MunicipalityAges 25–60 - NCT06446050RecruitingEarly Phase 1
Modified stem cells for advanced colorectal cancer
This trial tests a new treatment using special stem cells (modified to boost your immune system) for people with advanced colorectal cancer. It is for patients who are 18 or younger and whose cancer has not responded to or cannot be treated with standard therapies.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT03618550RecruitingPhase 2
Pembrolizumab plus chemotherapy for relapsed Hodgkin lymphoma
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
Duarte, CaliforniaAges 18 years+ - NCT03055247RecruitingPhase 2
Try ibuprofen plus growth factor and stem-cell mobilizer for X-CGD
This trial tests a combination of medicines to help your body release (“mobilize”) stem cells for future treatment in people with X-linked chronic granulomatous disease (X-CGD). If it works well and is safe for you, it may make stem-cell collection easier and more successful.
Rome, LazioAges 18–45 - NCT03403699Recruiting
Stem cell treatment for damaged eye blood vessels in diabetes
This study tests human iPSC–derived (lab-grown) cells aimed at repairing fragile, damaged blood vessels in diabetic retinopathy. It also involves eye exams and a small skin biopsy to support the research.
Birmingham, AlabamaAges 21–98 - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70
Hear when a new Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell transplantation?
- Yes. Clin2 currently lists 604 recruiting stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.